On the technicalities of discovering and applying protein biomarkers for cancer prevention

European Journal of Cancer Prevention

Volumn 13, Issue 5, 2004, Pages 437-446

  Kas, K ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Cancer prevention biomarkers; Protein biomarker profile

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CURCUMIN; CURCUMINOID; CYTOKINE; DNA; MESSENGER RNA; NATURAL PRODUCT; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TERPENE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; COLON CANCER; DIET; DISEASE MARKER; DRUG APPROVAL; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; ENVIRONMENTAL EXPOSURE; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; LIFESTYLE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEOMICS; REVIEW; TARGET CELL; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CHEMOPREVENTION; HUMANS; LIFE STYLE; NEOPLASMS; PROTEINS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 5044233196     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200410000-00012     Document Type: Review

References (37)

1. Adam BL, Qu Y, Davis JW, et al. (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-3614.
2. Aebersold R, Mann M (2003). Mass spectrometry-based proteomics. Nature 422: 198-207.
3. Anderson NL, Anderson NG (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867.
4. Anderson NL, Polanski M, Pieper R, et al. (2004). The human plasma proteome: a non-redundant list developed by combination of four separate sources. Mol Cell Proteomics 3: 311-326.
5. Banks RE, Dunn MJ, Forbes MA, et al. (1999). The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis-preliminary findings. Electrophoresis 20: 689-700.
6. Barnidge DR, Dratz EA, Martin T, et al. (2003). Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. Anal Chem 75: 445-451.
7. Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI (2003). Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 3: 2147-2154.
8. Cagney G, Emili A (2002). De novo peptide sequencing and quantitative profiling of complex protein mixtures using mass-coded abundance tagging. Nat Biotechnol 20: 163-170.
9. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science 246: 64-71.
10. Frank R, Hargreaves R (2003). Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580.
11. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 100: 6940-6945.
12. Gevaert K, Van Damme J, Goethals M, et al. (2002). Chromatographic isolation of methionine-containing peptides for gel-free proteome analysis: identification of more than 800 Escherichia coli proteins. Mol Cell Proteomics 1: 896-903.
13. Gevaert K, Goethals M, Martens L, et al. (2003). Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol 21: 566-569.
14. Gygi SP, Rist B, Gerber SA, et al. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17: 994-999.
15. Hanif R, Qiao L, Shiff SJ, Rigas B (1997). Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med. 130:576-584.
16. Joos TO, Schrenk M, Hopfl P, et al. (2000). A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 21: 2641-2650.
17. Hillenkamp F, Karas M (1990). Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol 193: 280-295.
18. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304.
19. Martin KJ, Graner E, Li Y, et al. (2001). High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci USA 98: 2646-2651.
20. Michaud GA, Salcius M, Zhou F, et al. (2003). Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol 21: 1509-1512.
21. O'Regan RM, Jordan VC (2002). The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3: 207-214.
22. Patterson SD, Aebersold RH (2003). Proteomics: the first decade and beyond. Nature Genetics 33(Suppl): 311-323.
23. Petricoin EF, Ardekani AM, Hitt BA, et al. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577.
24. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S (2003). Protein analysis on a proteomic scale. Nature 422: 208-215.
25. Poon TC, Yip TT, Chan AT, et al. (2003). Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49: 752-760.
26. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M (2003). Mass spectrometry-based clinical proteomics. Pharmacogenomics 4: 463-476.
27. Sauter ER, Zhu W, Fan XJ, et al. (2002). Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 86: 1440-1443.
28. Sreekumar A, Nyati MK, Varambally S, et al. (2001). Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 61: 7585-7593.
29. Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL (1998). Effects of the antitumor agent perillyl alcohol on H-Ras vs K-Ras famesylation and signal transduction in pancreatic cells. Anticancer Res 18: 823-828.
30. Templin MF, Stoll D, Schwenk JM, et al. (2003). Protein microarrays: promising tools for proteomic research. Proteomics 3: 2155-2166.
31. Vamum SM, Covington CC, Woodbury RL, et al. (2003). Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 80: 87-97.
32. Wang S, Regnier FE (2001). Proteomics based on selecting and quantifying cysteine containing peptides by covalent chromatography. J Chromatogr A 924: 345-357.
33. Washburn MP, Wolters D, Yates JR, III (2001). Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19: 242-247.
34. Wulfkuhle JD, Liotta LA, Petricoin EF (2003). Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-275.
35. Yanagisawa K, Shyr Y, Xu BJ, et al. (2003). Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362: 433-439.
36. Zhou H, Ranish JA, Watts JD, Aebersold R (2002). Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry. Nat Biotechnol 20: 512-515.
37. Zhu W, Wang X, Ma Y, et al. (2003). Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci USA 100: 14666-14671.